NasdaqGS:VTRS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Viatris Inc., a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. More Details


Snowflake Analysis

Reasonable growth potential and fair value.


Similar Companies

Share Price & News

How has Viatris's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VTRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: VTRS's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-18.5%

VTRS

-2.2%

US Pharmaceuticals

-3.6%

US Market


1 Year Return

-13.6%

VTRS

15.3%

US Pharmaceuticals

36.5%

US Market

Return vs Industry: VTRS underperformed the US Pharmaceuticals industry which returned 15.2% over the past year.

Return vs Market: VTRS underperformed the US Market which returned 36.4% over the past year.


Shareholder returns

VTRSIndustryMarket
7 Day-18.5%-2.2%-3.6%
30 Day-12.6%-1.9%2.7%
90 Day-11.7%5.6%7.5%
1 Year-13.6%-13.6%19.1%15.3%39.5%36.5%
3 Year-63.8%-63.8%28.3%18.3%53.5%43.6%
5 Year-66.8%-66.8%46.1%28.8%117.5%93.2%

Long-Term Price Volatility Vs. Market

How volatile is Viatris's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Viatris undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VTRS ($14.85) is trading below our estimate of fair value ($70.09)

Significantly Below Fair Value: VTRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VTRS is poor value based on its PE Ratio (28.8x) compared to the US Pharmaceuticals industry average (27.9x).

PE vs Market: VTRS is poor value based on its PE Ratio (28.8x) compared to the US market (21.3x).


Price to Earnings Growth Ratio

PEG Ratio: VTRS is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: VTRS is good value based on its PB Ratio (0.6x) compared to the US Pharmaceuticals industry average (4.4x).


Next Steps

Future Growth

How is Viatris forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

22.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTRS's forecast earnings growth (22.3% per year) is above the savings rate (2%).

Earnings vs Market: VTRS's earnings (22.3% per year) are forecast to grow faster than the US market (20.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VTRS's revenue (6.4% per year) is forecast to grow slower than the US market (10.4% per year).

High Growth Revenue: VTRS's revenue (6.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VTRS's Return on Equity is forecast to be high in 3 years time (30.8%)


Next Steps

Past Performance

How has Viatris performed over the past 5 years?

-32.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VTRS has a large one-off loss of $861.8M impacting its September 30 2020 financial results.

Growing Profit Margin: VTRS's current net profit margins (2.3%) are higher than last year (0.4%).


Past Earnings Growth Analysis

Earnings Trend: VTRS's earnings have declined by 32.1% per year over the past 5 years.

Accelerating Growth: VTRS's earnings growth over the past year (464.8%) exceeds its 5-year average (-32.1% per year).

Earnings vs Industry: VTRS earnings growth over the past year (464.8%) exceeded the Pharmaceuticals industry -3.5%.


Return on Equity

High ROE: VTRS's Return on Equity (2.1%) is considered low.


Next Steps

Financial Health

How is Viatris's financial position?


Financial Position Analysis

Short Term Liabilities: VTRS's short term assets ($7.3B) exceed its short term liabilities ($7.3B).

Long Term Liabilities: VTRS's short term assets ($7.3B) do not cover its long term liabilities ($11.4B).


Debt to Equity History and Analysis

Debt Level: VTRS's debt to equity ratio (97.9%) is considered high.

Reducing Debt: VTRS's debt to equity ratio has increased from 65.8% to 97.9% over the past 5 years.

Debt Coverage: VTRS's debt is not well covered by operating cash flow (15.3%).

Interest Coverage: VTRS's interest payments on its debt are well covered by EBIT (3.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Viatris's current dividend yield, its reliability and sustainability?

2.89%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VTRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VTRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VTRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Michael Goettler (52 yo)

no data

Tenure

Mr. Michael Goettler serves as Chief Executive Officer and Executive Director at Viatris Inc. Mr. Goettler is a Member of the Board of Directors of Population Services International (PSI). Mr. Goettler ser...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Coury
Executive Chairman of the Board4.67yrsUS$1.83m0.11%
$ 20.5m
Rajiv Malik
President & Executive Director8yrsUS$12.38m0.045%
$ 8.1m
Anthony Mauro
President of Developed Markets5.08yrsUS$5.75m0%
$ 0
Michael Goettler
CEO & Executive Directorno datano data0.00050%
$ 90.1k
Sanjeev Narula
Chief Financial Officer0.25yrno data0.00060%
$ 108.1k
Sanjeev Sethi
Chief Operating Officerno datano datano data
Paul Campbell
Chief Accounting Officerno datano data0.0026%
$ 464.7k
Ramkumar Rayapureddy
Chief Information Officerno datano datano data
Brian Roman
Global General Counselno datano datano data
David Bayles
Chief Compliance Officerno datano datano data
Jennifer Mauer
Head of Global Communications & Corporate Brandno datano datano data
William Szablewski
Head of Capital Marketsno datano datano data

3.0yrs

Average Tenure

53yo

Average Age

Experienced Management: VTRS's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Coury
Executive Chairman of the Board4.67yrsUS$1.83m0.11%
$ 20.5m
Rajiv Malik
President & Executive Director8yrsUS$12.38m0.045%
$ 8.1m
Michael Goettler
CEO & Executive Directorno datano data0.00050%
$ 90.1k
JoEllen Dillon
Independent Non-Executive Director6.83yrsUS$440.01k0.0013%
$ 232.4k
W. Cornwell
Director0.25yrno datano data
Neil Dimick
Independent Non-Executive Director15.33yrsUS$430.01k0.0042%
$ 762.0k
James Kilts
Director0.25yrno data0.0053%
$ 963.7k
Harry Korman
Independent Non-Executive Director2.67yrsUS$360.01k0.0022%
$ 396.3k
Melina Higgins
Independent Non-Executive Director8yrsUS$398.76k0.0093%
$ 1.7m
Mark Parrish
Independent Director11.42yrsUS$520.01k0.0048%
$ 866.4k
Pauline Francoise van der Meer Mohr
Independent Non-Executive Director2.67yrsUS$345.01k0.00052%
$ 93.7k
Richard Mark
Independent Non-Executive Director1.67yrsUS$277.51k0.00076%
$ 136.9k

4.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: VTRS's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VTRS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 135%.


Top Shareholders

Company Information

Viatris Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viatris Inc.
  • Ticker: VTRS
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$18.013b
  • Shares outstanding: 1.21b
  • Website: https://www.viatris.com

Number of Employees


Location

  • Viatris Inc.
  • 1000 Mylan Boulevard
  • Canonsburg
  • Pennsylvania
  • 15317
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VTRS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNFeb 1973
VIADB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1973
VTRSETLX (Eurotlx)YesCommon StockITEURFeb 1973
VTRSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1973
VIAXTRA (XETRA Trading Platform)YesCommon StockDEEURFeb 1973

Biography

Viatris Inc., a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. Its portfolio comprises approximately 1,400 approved molecules acro...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/01 01:10
End of Day Share Price2021/02/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.